Lataa...
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAF(V600)-Mutated Nonmelanoma Tumors
BRAF(V600) mutations occur in multiple nonmelanoma tumors, but no US Food and Drug Administration–approved BRAF-targeted therapies exist for these cancers. BRAF inhibitor vemurafenib was recently found to demonstrate activity across various BRAF-mutated nonmelanoma cancer types. However, most tumors...
Tallennettuna:
| Julkaisussa: | J Natl Cancer Inst |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6059192/ https://ncbi.nlm.nih.gov/pubmed/29117359 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx094 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|